Open Actively Recruiting

EASE: The Materna Prep Pivotal Study

About

Brief Summary

This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery.

Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device during delivery.
Primary Purpose
Other
Study Type
Interventional
Phase
N/A

Eligibility

Gender
Female
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Criteria for inclusion

  • Subject is scheduled for vaginal birth.
  • Subject is gestating a single fetus.
  • Subject is nulliparous, or had a previous pregnancy terminated within 24 weeks gestation.
  • Subject is able and willing to comply with the protocol required follow-up visits.
  • Subject is able and willing to provide written informed consent prior to enrollment.
  • In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF), comply with the protocol requirements, and provide clinically relevant and reliable feedback regarding their experience with the device.
  • Subject receives epidural anesthesia during labor prior to enrollment.
  • Subject is 18 years of age or older at time of consent.

Exclusion Criteria:

Criteria for exclusion

  • Subject has high likelihood of less than 1 hour of potential device dilation time after she arrives at the hospital.
  • Subject is planning or requires a Caesarean-section prior to randomization.
  • Subject begins labor with less than 36 weeks gestation.
  • Subject has a neurological disorder that could cause pelvic floor dysfunction, such as multiple sclerosis or spinal cord injury.
  • Subject has a collagen-associated disorder that affects tissue elasticity, such as scleroderma or Ehlers-Danlos syndrome.
  • Subject has a localized (genital tract) or systemic infection.
  • Subject has a medical history which could lead to pelvic floor dysfunction, such as prior pelvic fractures, pelvic soft tissue injuries, or vaginal surgery.
  • Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.
  • Subject has placenta previa or vasa previa.
  • Subject has known significant chromosomal or structural fetal anomalies.
  • Subject has a category 2 and/or 3 fetal tracing that is unresolved.
  • Subject is observed to have friable, denuded, or markedly edematous vaginal tissue during the course of labor.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
21-000156
Category
Pregnancy
Contact
DANA LEVIN-LOPEZ
Location
  • UCLA Santa Monica
  • UCLA Westwood
For Providers
NCT No.
NCT03973281
For detailed technical eligibility, visit ClinicalTrials.gov.